Sign in
4

Changes in Ownership

Monopar Therapeutics Filed Acc 0001437749-26-035040

Director sold 3,142 shares at an average $68.35 ($214,746)

  • Director acquired 3,142 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Anderson Raymond · Director

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-11-02 Exercise or conversion : show line 1 in the form 10b5-1 +1,402 $30.00 $42,058 6,775 D
2026-11-02 Exercise or conversion : show line 2 in the form 10b5-1 +1,740 $30.00 $52,200 8,515 D
2026-11-02 Sale : show line 3 in the form 10b5-1 −840 $66.16 $55,574 7,675 D
2026-11-02 Sale : show line 4 in the form 10b5-1 −600 $67.06 $40,236 7,075 D
2026-11-02 Sale : show line 5 in the form 10b5-1 −200 $68.68 $13,736 6,875 D
2026-11-02 Sale : show line 6 in the form 10b5-1 −1,502 $70.04 $105,200 5,373 D
Open-market sales · 3,142 sh · avg $68.35 · $214,746

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-11-02 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option −1,402 1,401 D
2026-11-02 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option −1,740 1,740 D
Loading xslF345X06/rdgdoc.xml…